Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 4 Interventional

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

ClinicalTrials.gov ID: NCT07285785

Public ClinicalTrials.gov record NCT07285785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes

Study identification

NCT ID
NCT07285785
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Bausch Health Americas, Inc.
Industry
Enrollment
54 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 12 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 10, 2026
Primary completion
Apr 19, 2027
Completion
Jul 30, 2027
Last update posted
Aug 12, 2026

2026 – 2027

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Alliance Research Institute Lynwood California 90262 Recruiting
Direct Helpers Hialeah Florida 33012 Recruiting
SouthCoast Research Center Miami Florida 33136 Recruiting
Oceane7 Medical & Research Center, Inc Miami Florida 33144 Recruiting
Rophe Adult & Pediatric Medicine Union City Georgia 30291 Recruiting
Innovative Clinical Research Center Island Lake Illinois 60042 Recruiting
Cyn3rgy Research Corporation Gresham Oregon 97030 Recruiting
Little Stars Pediatrics / Tattva Trials Prosper Texas 75078 Recruiting
LinQ Research Rosharon Texas 77583 Recruiting
Tekton Research Richmond Virginia 23233 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07285785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07285785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →